Glibert Pieter

Pieter Glibert

phone: ++32 9 264 83 56
fax: ++32 9 220 66 88


Evaluation of a new prognostic marker in chronic lymphocytic leukemia


Chronic lymphocytic leukemia (CLL) is a neoplastic disease which is characterized by the accumulation of B lymphocytes in the blood, marrow and lymphoid tissue. Since the individual prognosis of patients with CLL is extremely variable, several biological markers predict the clinical outcome of the disease.  Used assays however, are difficult-to-perform or have problems with standardization and interpretation.

In this study the predictive value of a new epigenetic marker and his role in CLL will be characterized. Gel - and mass spectrometry-based quantitative proteomics will be applied to compare this new identified modification in cells, isolated from B-chronic lymphocytic leukemia patients at different stages.